Cresco Labs Q3 2026: Revenue $173M, Adjusted EBITDA $35M, Net Loss $15M
CRLBF is trading near its 52-week low of $0.554 (2.6% above the low).
Summary
Cresco Labs reported Q3 2026 revenue of $172.8M (+4.8% year-over-year) and Adjusted EBITDA of $34.9M, down 12.3% as SG&A climbed 16.3%. Operating cash flow of $26.1M and a $26.7M medical-cannabis tax benefit offset a $14.5M quarterly net loss.
Key Events · Earnings and Guidance · CRLBF
-
Q3 Revenue Up 4.8% to $172.8M
Revenue rose to $172.8M from $164.9M a year earlier, driven by Pennsylvania dispensary acquisitions and Ohio store openings, partly offset by Illinois price compression and the California exit.
-
Adjusted EBITDA Falls 12.3%
Adjusted EBITDA was $34.9M (20.2% margin) versus $39.8M (24.1%) a year ago, as SG&A increased 16.3% to $68.8M and gross margin slipped to 46.0% from 48.1%.
-
Cash Generation Holds Up
Operating cash flow was $26.1M and free cash flow $21.2M for the quarter; cash, equivalents and restricted cash totaled $75.8M against $454M of long-term notes and loans payable.
-
Tax Benefit Narrows Nine-Month Loss
A $26.7M net tax benefit from the April 22, 2026 removal of IRC Section 280E for state-licensed medical cannabis cut the nine-month net loss to $16.2M from $51.1M.
Analysis · CRLBF · Life Sciences
The top line is expanding while margins compress: revenue grew 4.8% to $172.8M, but Adjusted EBITDA fell 12.3% to $34.9M as SG&A rose 16.3%. Cash generation is the offset, with $26.1M of operating cash flow and $21.2M of free cash flow for the quarter—a critical cushion given a stock near its 52-week low and $454M of long-term debt against $41.2M of unrestricted cash. A $26.7M tax benefit tied to the April 2026 rescheduling of state-licensed medical cannabis cut the nine-month net loss to $16.2M from $51.1M, a real cash-tax tailwind rather than an accounting one-off. The PharmaCann deal closed September 1, 2026 for $46.9M, adding nine Pennsylvania dispensaries and shifting the mix toward retail.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRLBF was trading at $0.57 on OTC in the Life Sciences sector, with a market capitalization of approximately $259.8M. The 52-week trading range was $0.55 to $2.30. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.